{
    "nct_id": "NCT03373006",
    "official_title": "A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer",
    "inclusion_criteria": "1. Male, 45 years of age or older.\n2. Diagnosis of prostate adenocarcinoma.\n3. Clinical stage T1a, T1b, T1c, T2a, T2b orT2c.\n4. Gleason score of 7 (3+4 or 4+3).\n5. PSA density less than 0.375.\n6. One, two, or three tumor suspicious regions identified on multiparametric MRI.\n7. Negative radiographic indication of extra-capsular extent.\n8. Karnofsky performance status of at least 70.\n9. Estimated survival of 5 years or greater, as determined by treating physician.\n10. Tolerance for anesthesia/sedation.\n11. Ability to give informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 45 Years",
    "exclusion_criteria": "1. Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.\n2. Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater. ( (http://www.urospec.com/uro/Forms/ipss.pdf)\n3. History of other Primary non-skin malignancy within previous three years.\n4. Diabetes.\n5. Smoker.",
    "miscellaneous_criteria": ""
}